Vedana Therapeutics develops precision small-molecule therapies that modulate protein homeostasis pathways to treat neurodegenerative diseases.
Investors 1
| Date | Name | Website |
| 10.07.2026 | Canaan Par... | canaan.com |
Mentions in press and media 5
| Date | Title | Description |
| 22.06.2026 | Nura Bio Raises $73.8M in Series B Funding | Nura Bio Inc., South San Francisco, CA-based clinical-stage biopharmaceutical company developing neuroprotective small molecule therapies, raised $73.8M in Series B funding. The round was led by The Column Group, with participation from Euc... |
| 22.06.2026 | Vedana Therapeutics Raises $46M in Series A Funding | Vedana Therapeutics, a Seattle, WA-based biotechnology company developing new therapies for migraine prevention, raised $46M in Series A funding. The round was led by Westlake BioPartners and Canaan Partners, with participation from Dawn Bi... |
| 19.06.2026 | Vedana Therapeutics Raises $46 Million To Advance Next-Generation Migraine Therapies | Vedana Therapeutics emerged from stealth with $46 million in Series A funding to advance next-generation therapies for migraine prevention. The funding round was co-led by Westlake BioPartners and Canaan Partners, with participation from Da... |
| 17.06.2026 | Vedana Therapeutics surfaces with $46M to develop next generation of migraine prevention therapies | Vedana Therapeutics has emerged from stealth with $46 million in series A financing aimed at advancing the company’s subcutaneously delivered antibodies for migraine prevention. The financing was co-led by Westlake BioPartners and Canaan Pa... |
| - | Vedana Therapeutics | - |